Amgen wins broader Vectibix use with Qiagen Dx in mCRC
This article was originally published in Scrip
Executive Summary
The FDA on 23 May gave Amgen the go-ahead to market Vectibix (panitumumab), a fully human anti-epidermal growth factor receptor (EGFR) antibody, in combination with FOLFOX (folinic acid, fluorouracil and oxaliplatin) chemotherapy as a first-line treatment for patients with wild-type KRAS metastatic colorectal cancer (mCRC).